Innovative Nanotherapy Targets Fat Absorption to Combat Obesity

New nanoparticle treatment reduces fat absorption in the small intestine, offering a promising non-invasive obesity solution.

Researchers have developed a nanoparticle system that inhibits the enzyme SOAT2, crucial for fat absorption in the small intestine.
The treatment uses small interfering RNAs (siRNAs) delivered to the intestine, reducing fat uptake and preventing obesity in mice.
This approach allows normal eating habits without increasing fat absorption, potentially improving patient compliance.
Unlike previous methods, this therapy avoids liver fat accumulation by targeting only intestinal SOAT2.
Further testing in larger animal models is planned to assess the treatment's safety and effectiveness for human use.